The Mevalonate Pathway Is Indispensable for Adipocyte Survival

Yu-Sheng Yeh, Huei-Fen Jheng, Mari Iwase, ..., Wataru Nomura, Teruo Kawada, Tsuyoshi Goto
tgoto@kais.kyoto-u.ac.jp

HIGHLIGHTS

- HMGCR deficiency in adipocytes causes lipodystrophy
- HMGCR deficiency in adipocytes triggers several metabolic disorders
- Cholesterol and pioglitazone cannot improve HMGCR-deficiency-induced lipodystrophy
- GGPP is critical for adipocyte survival by regulating apoptosis

Yeh et al., iScience 9, 175–191 November 30, 2018 © 2018 The Authors. https://doi.org/10.1016/j.isci.2018.10.019
The Mevalonate Pathway Is Indispensable for Adipocyte Survival

Yu-Sheng Yeh,1 Huei-Fen Jheng,1 Mari Iwase,1 Minji Kim,1 Shinsuke Mohri,1 Jungin Kwon,1 Satoko Kawarasaki,1 Yongjia Li,1 Haruya Takahashi,1 Takeshi Ara,1 Wataru Nomura,1,2 Teruo Kawada,1,2 and Tsuyoshi Goto1,2,3,*

SUMMARY
The mevalonate pathway is essential for the synthesis of isoprenoids and cholesterol. Adipose tissue is known as a major site for cholesterol storage; however, the role of the local mevalonate pathway and its synthesized isoprenoids remains unclear. In this study, adipose-specific mevalonate pathway-disrupted (aKO) mice were generated through knockout of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (HMGCR). aKO mice showed serious lipodystrophy accompanied with glucose and lipid metabolic disorders and hepatomegaly. These metabolic variations in aKO mice were dramatically reversed after fat transplantation. In addition, HMGCR-disrupted adipocytes exhibited loss of lipid accumulation and an increase of cell death, which were ameliorated by the supplementation of mevalonate and geranylgeranyl pyrophosphate but not farnesyl pyrophosphate and squalene. Finally, we found that apoptosis may be involved in adipocyte death induced by HMGCR down-regulation. Our findings indicate that the mevalonate pathway is essential for adipocytes and further suggest that this pathway is an important regulator of adipocyte turnover.

INTRODUCTION
The mevalonate (MVA) pathway produces sterols, especially cholesterol, which is essential for cell membrane structure, bile acids, and steroid hormones (Goldstein and Brown, 1990). Moreover, the MVA pathway is also known to synthesize isoprenoids, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), which are essential sources of protein prenylation (Casey, 1992). In particular, prenylation comprises a post-translational process that modifies a multitude of proteins involved in protein synthesis and glycosylation, intracellular signaling, gene expression, and cell growth (Casey, 1992; Goldstein and Brown, 1990). In addition, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (HMGCR), a rate-limiting enzyme in the MVA pathway, catalytically converts HMG-CoA to MVA and is further repressed via negative feedback regulation (Goldstein and Brown, 1990).

As the MVA pathway affects various metabolic pathways, inhibitors of HMGCR, also known as statins, have been extensively used in the clinic as an effective treatment for hypercholesterolemia, in addition to being considered as potential treatments for certain features of cardiovascular disease and hepatic disorders (Kamal et al., 2017; Wadhera et al., 2016). However, accumulating data indicate that the usage of statins has certain unexpected cholesterol-independent pleiotropic effects, such as increased risk of new-onset diabetes or muscle disorders (Thompson et al., 2003; Zaharan et al., 2013). Skeletal muscle-specific HMGCR knockout mice also exhibited similar symptoms (Osaki et al., 2015). Furthermore, disruption of HMGCR in the liver, the major target organ for statin metabolism, has been reported to cause liver steatosis and death (Nagashima et al., 2012). These phenomena are thought to be caused by insufficient intermediate products generated in the MVA pathway (Bang and Ökin, 2014; Brault et al., 2014) and suggest that HMGCR is important for mammals and plays a different role in each organ.

Obesity, defined as an increase in adipose tissue mass, is thought to be highly related to lipid metabolism diseases, such as hypercholesterolemia (Fasshauer and Bluher, 2015; Lackey and Olefsky, 2016). In addition, adipose tissue is known to be the major organ for cholesterol storage, thus serving an important function in regulating systemic cholesterol metabolism (Bays et al., 2013; Krause and Hartman, 1984). However, the role of the MVA pathway in adipose tissue remains completely unknown. Previous studies have shown that MVA-derived metabolites, such as FPP and GGPP, serve as endogenous regulators of adipocyte function (Goto et al., 2011; Yeh et al., 2016). Moreover, MVA pathway-related gene expression is partially enhanced in the adipose tissue of an obese/diabetic mouse model (Yeh et al., 2016; Yu et al., 2011). These
Figure 1. aKO Mice Exhibit Lipodystrophy and Diabetic Symptoms

(A) Schematic illustration of the mevalonate pathway.

(B) Body weight change of control (Ctrl) and aKO mice.

(C) Relative fat and lean mass levels of 15-week-old Ctrl and aKO mice.

(D) Gross morphology of iWAT (top panel), eWAT (also the liver, middle panel), and BAT (bottom panel) of Ctrl and aKO mice at 32 weeks of age. The arrows indicate the tissue position.

(E) H&E-stained tissue sections of iWAT (top panel), eWAT (middle panel), and BAT (bottom panel) from Ctrl and aKO mice at 32 weeks of age. Scale bars, 200 μm.

(F) Adipose tissue weights of Ctrl and aKO mice at 32 weeks of age.
results reveal that isoprenoids may play an important role in the regulation of adipose tissue function. Thus, to further clarify the detailed role of isoprenoids in adipose tissue function, we generated adipose-specific MVA pathway-disrupted (aKO) mice through specific knockout of HMGCR in adipose tissue. Here, we show that the MVA pathway in adipocytes is both necessary and sufficient to maintain adipocyte survival, which in turn further influences systemic homeostasis.

RESULTS

aKO Mice Show Systemic Lipodystrophy

To study the role of the MVA pathway (Figure 1A) in adipose tissues, we generated aKO mice using the Cre-loxP system. The floxed HMGCR mice, designed as shown in Figure S1A, were crossed with adiponectin-Cre mice (Eguchi et al., 2011). HMGCR knockout alleles were observed only in the genomic DNA extracted from white adipose tissue (WAT) and brown adipocyte tissue (BAT) and not in the DNA from other tissues in heterozygous aKO mice (Figure S1B).

Eight-week-old male (Figures 1, 2, and 3) and female mice (Figure S2) were used. The body weights of aKO mice of both genders were higher than those of control (Ctrl) mice (Figures 1B and S2A). Whole-body MRI scanning showed that fat mass was drastically decreased, whereas lean mass was slightly increased in aKO mice (Figures 1C and S2B). As shown in Figure 1D, we observed that aKO mice lost almost all fat pads, including inguinal WAT (iWAT), epididymal WAT (eWAT), and BAT. Furthermore, compared with Ctrl mice, a very limited number of lipid-laden adipocytes was observed in adipose tissues (iWAT, eWAT, and BAT) in aKO mice (Figure 1E). Consistent with the appearance of WAT and BAT, the tissue weight and levels of plasma adipokines including adiponectin and leptin were extremely reduced in aKO mice (Figures 1F–1H and S2C–S2E). Although the consumption of a high-fat diet (HFD) reversed the difference in body weight gain between the two genotype groups (Figure S3A), this appeared to mainly result from increases of fat weight in the Ctrl group rather than from lipodystrophy amelioration in the aKO group (Figures S3B–S3E). These results suggest that HMGCR in the adipose tissue plays a critical role in the maintenance of adipose mass and adipokine levels.

aKO Mice Exhibit Severe Diabetes

Food intake and water consumption in aKO mice were obviously higher than those in Ctrl mice (Figures 1I, 1J, S2F, and S2G). Moreover, the non-fasting plasma glucose and insulin levels were markedly enhanced in aKO mice in both the normal diet (ND) (Figures 1K, 1L, S2H, and S2I) and HFD (Figures S3F and S3G) conditions, suggesting that glucose metabolism was disrupted in aKO mice. The glucose tolerance test (GTT) showed that plasma glucose levels were significantly higher in aKO mice after oral glucose administration, and the area under the curve also showed that glucose tolerance was reduced in aKO mice (Figure 1M). In the insulin tolerance test (ITT), plasma glucose levels were effectively reduced after insulin injection in Ctrl mice but not in aKO mice (Figure 1N). Female mice also showed similar results in GTT and ITT (Figures S2J and S2K). These results clearly show that ablation of HMGCR in adipose tissues induced lipodystrophy accompanied by severe dysfunction of glucose metabolism.

aKO Mice Develop Ectopic Lipid Deposition in the Liver

Both male and female aKO mice had enlarged liver (Figures 2A and S2L, Table S2). Moreover, many bubble-like areas were found in liver sections of aKO mice stained with hematoxylin and eosin (H&E) (Figure 2A). Oil red O staining indicated obviously increased lipid droplets in aKO compared with Ctrl mice (Figure 2A). Consistent with this finding, hepatic triglyceride (TG) accumulation in aKO mice was enhanced (Figures 2B and S2M). As shown in Figure 2C, hepatic lipid-synthesis-related genes, such as sterol regulatory element-binding protein 1 (Srebf1), fatty acid synthase (Fasn), and peroxisome
proliferator-activated receptor gamma (Pparg), were highly expressed in aKO compared with Ctrl mice, whereas very limited changes were observed in lipid-oxidation-related gene expression, including that of acyl-coenzyme A oxidase 1 (Acox1), carnitine palmitoyltransferase IA (Cpt1a), and peroxisome proliferator-activated receptor alpha (Ppara). These results suggest that increased hepatic lipid accumulation in aKO mice might mainly result from the up-regulation of lipid biosynthesis. In addition, hepatic liver glycogen showed a 2.5-fold increase in aKO mice compared with Ctrl mice, and hepatic gluconeogenesis-related gene expression, such as that of phosphoenolpyruvate carboxykinase (Pck1), glucose-6-phosphatase (G6pc), and fructose-1,6-bisphosphate (Fbp1), was also higher in aKO compared with Ctrl mice (Figures 2D and 2E). These data suggest that adipose-disrupted HMGCR possibly affected hepatic glucose metabolism.

The activities of plasma glutamic-oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT), the main hepatic injury markers, were significantly elevated in aKO compared with Ctrl mice, whereas very limited changes were observed in lipid-oxidation-related gene expression, including that of acyl-coenzyme A oxidase 1 (Acox1), carnitine palmitoyltransferase IA (Cpt1a), and peroxisome proliferator-activated receptor alpha (Ppara). These results suggest that increased hepatic lipid accumulation in aKO mice might mainly result from the up-regulation of lipid biosynthesis. In addition, hepatic liver glycogen showed a 2.5-fold increase in aKO mice compared with Ctrl mice, and hepatic gluconeogenesis-related gene expression, such as that of phosphoenolpyruvate carboxykinase (Pck1), glucose-6-phosphatase (G6pc), and fructose-1,6-bisphosphate (Fbp1), was also higher in aKO compared with Ctrl mice (Figures 2D and 2E). These data suggest that adipose-disrupted HMGCR possibly affected hepatic glucose metabolism.

All mice were male and fed a normal diet (ND). Values are presented as mean ± SE. (n = 6–8). Significant differences were determined by Student’s t test compared with Ctrl: *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2.
Adipose-Specific Disruption of HMGCR Alters the Pattern of Energy Expenditure

Although locomotor activity was significantly reduced in aKO mice (Figures 2I and S2O), the oxygen consumption rate was increased compared with Ctrl mice (Figures 2Ja and S2P). The respiratory exchange ratio (RER) was decreased in aKO mice in the dark state, suggesting that aKO mice prefer to use fatty acid as an energy source compared with Ctrl mice (Figures 2Ka and S2Q). Consistent with the RER results, we found that plasma β-hydroxybutyric acid (β-HB), a type of ketone body metabolized from fatty acid, was up-regulated, accompanied by an increase of several lipids, such as TG, free fatty acid (FFA), and cholesterol (Figures 3La and S3R). Thus, these data indicate that adipose-specific HMGCR ablation disrupts lipid and energy metabolism, as well as locomotor activity.

Thiazolidinedione Improves Glucose-Metabolic Disorders without Rescuing Adipose Tissue Mass in aKO Mice

A previous study reported that MVA metabolites could modulate PPARγ activity, which plays a central role in adipocyte differentiation (Goto et al., 2011). Therefore, to examine whether lipodystrophy in aKO mice resulted from a reduction of PPARγ activity, we next orally administered a synthetic PPARγ agonist (pioglitazone [Pio], 30 mg/kg/day) to the mice for 10 weeks. Although Pio treatment reduced body weight gain and enhanced fat mass in aKO mice, the lack of adipose tissue in aKO mice was not improved (Figures S4A–S4C). Furthermore, Pio treatment further aggravated hepatomegaly, hepatic TG accumulation, and enhanced plasma GOT and GPT activities in aKO mice (Figure S4D). Pio treatment increased the plasma adiponectin level and decreased the plasma leptin level in Ctrl mice but had no such effects in aKO mice (Figures S4E and S4F). Although Pio failed to rescue the fat mass, the hyperphagia, hyperdipsia, hyperglycemia, and hyperinsulinemia were ameliorated by Pio treatment in aKO mice (Figures S4G–S4J). Taken together, these results indicate that PPARγ agonist treatment improved several metabolic disorders independently of adipose tissue function in aKO mice, suggesting that HMGCR-mediated lipodystrophy was minimally associated with the deficiency of MVA-derivative PPARγ ligands.

Implantation of Adipose Tissue Reverses Diabetic Consequences in aKO Mice

Next, to investigate whether metabolic abnormalities in aKO mice were related to lipodystrophy, we performed WAT implantation. At 16 weeks after implantation, the fat grafts were successfully implanted subcutaneously and their weight was enhanced by approximately 1.8-fold compared with the initially transplanted fat weight (Figure S5A). The transplanted fat pads exhibited blood vessel formation and showed normal histology (Figures S5B and S5C). At six weeks after surgery, sham-operated (Sham) mice were significantly heavier than Ctrl and transplanted (Transplant) mice, which showed no significant difference in body weight (Figure 3A). Notably, however, fat implantation only resulted in mild recovery in plasma leptin and adiponectin levels (Figures 3B and 3C). Furthermore, we found that the enhanced food intake and water consumption in Sham mice were completely reversed by fat transplantation (Figures 3D and 3E). In addition, glucose metabolic disturbances including hyperglycemia, glucose intolerance, and insulin resistance in aKO mice were almost entirely reversed by fat transplantation (Figures 3F–3I). These results demonstrated that the severe diabetic symptoms occurring in adipose-specific HMGCR knockout were mainly due to WAT deficiency.

Implantation of Adipose Tissue Reverses Defects of Hepatic Metabolism in aKO Mice

We next addressed whether the defective hepatic phenomena in aKO mice could be improved through fat transplantation. As shown in Figure 4A, the abnormal liver appearance and hepatic histology in Sham mice were reversed in Transplant mice. Consistent with this finding, hepatic TG accumulation levels were normalized by fat transplantation in aKO mice (Figure 4B). The gene expression associated with lipid
synthesis was significantly up-regulated in the Sham compared with the Ctrl group, whereas such up-regulation was largely diminished in the Transplant group (Figure 4C). Furthermore, fat implantation also reversed the abnormalities in both total hepatic glycogen levels and gluconeogenesis-related gene expression in aKO mice (Figures 4D and 4E). These results suggest that both abnormal hepatic lipid and glucose metabolism in aKO mice mainly resulted from insufficient WAT.

Figure 4. Hepatic Function and Systemic Metabolism Are Improved in Fat-Transplanted aKO Mice
(A) Gross morphology of the liver (top panel) and liver sections stained with H&E (middle panel) and oil red O (bottom panel) at 16 weeks after surgery. Scale bars, 200 µm.
(B and C) Hepatic TG accumulation (B) and lipid metabolism-related gene expression (C) at 16 weeks after surgery.
(D and E) Hepatic glycogen (D) and gluconeogenesis-related gene expression (E) at 16 weeks after surgery.
(F–H) Plasma GOT and GPT activity (F), and hepatic inflammation- (G) and fibrosis- (H) related gene expression at 16 weeks after surgery.
(I–K) Locomotor activity (I), oxygen consumption (J), and RER (K) at 16 weeks after surgery.
(L) Plasma TG, FFA, cholesterol, and β-HB levels at 16 weeks after surgery.
Bars represent mean ± SE. (n = 6–8). Bars with different letters represent significant difference (p < 0.05) by one-way ANOVA with a post-hoc Tukey HSD test.
Consistent with liver appearance and morphological variation, the increased plasma GOT and GPT activities in the Sham group were both reduced to the levels in the Ctrl group by fat transplantation (Figure 4F). Moreover, inflammation- and fibrosis-related gene expression were increased in the Sham group, whereas these changes were significantly reversed in the Transplant group (Figures 4G and 4H). These results suggest that fat implantation likely improved hepatic inflammation and fibrosis in aKO mice.

**Fat Transplantation Partially Improves the Pattern of Energy Expenditure in aKO Mice**

Notably, the decreased locomotor activity was completely reversed by fat implantation in aKO mice (Figure 4I). As shown in Figure 4J, Sham mice showed higher oxygen consumption than Ctrl mice, whereas this enhancement was depressed in Transplant mice. Furthermore, based on the results of RER, the energy source was shifted from lipid to carbohydrate usage in aKO mice by fat transplantation (Figure 4K). Consistent with this finding, the increase in plasma b-HB level was reversed by fat implantation in aKO mice as well (Figure 4L), indicating that the disrupted lipid metabolism in aKO mice was possibly improved by fat transplantation. As expected, adipose tissue implantation reversed the up-regulation of plasma lipid levels in aKO mice (Figure 4L). These findings support that the disrupted metabolism and activity pattern in aKO mice might be largely due to an insufficiency of systemic adipose tissue.

**Inadequate HMGCR Causes Adipocyte Death In Vitro**

To examine why HMGCR deficiency causes lipodystrophy, we used lovastatin (Lova) to inhibit HMGCR activity in differentiated 3T3-L1 adipocytes. The stained lipid droplets and intracellular TG levels were obviously decreased in Lova-treated 3T3-L1 adipocytes, whereas these phenotypic variations were reversed in the presence of MVA or GGPP but not squalene or FPP (Figures S6A and S6B). Moreover, HMGCR inhibition extensively decreased cell viability, and this effect was prevented by MVA and GGPP (Figure S6C), as evidenced by the number of Hoechst-stained nuclei (Figure S6A). In addition, we isolated primary preadipocytes from the WAT of an HMGCR f/f mouse (primary WAT). Consistent with the other findings, in differentiated primary WAT cells, we found that the Lova-induced reduction in lipid accumulation was reversed by co-treatment with MVA or GGPP but not squalene or FPP (Figures 5A and 5B). Furthermore, the Lova-mediated reduction of adipocyte viability was ameliorated in the presence of MVA or GGPP (Figure 5C). Therefore, Lova-mediated inhibition of the MVA pathway leads to decreased adipocyte viability. Interestingly, MVA and GGPP but not FPP could completely prevent Lova-induced adipocyte death (Figures 5A–5C and S6A–S6C). However, treatment with isopentenyl pyrophosphate (IPP) alone failed to avert Lova-induced reduction of both lipid accumulation and Hoechst-stained nuclei, but successfully rescued these processes when combined with FPP in primary WAT cells (Figure S7). Therefore, both IPP, enzymatically synthesized from MVA, and FPP are required for GGPP synthesis.

To exclude the possibility of adipocyte death caused by cholesterol deficiency, cholesterol was added to Lova-treated primary WAT cells. As shown in Figures S8A and S8B, the Lova-decreased lipid accumulation and Hoechst-stained nuclei in primary WAT cells could not be restored to normal levels by cholesterol treatment. We also fed aKO mice with a high-cholesterol diet (HCD) for 6 weeks. Although the plasma cholesterol level in HCD-fed aKO mice was substantially higher than that in ND-fed aKO mice (Figure S8C), adipose tissue mass and plasma adipokine levels in HCD-fed aKO mice did not recover to normal levels (Figures S8D–S8G). These results clearly suggest that adipocyte death resulting from the inhibition of the MVA pathway was most likely not related to cholesterol insufficiency.
Next, to mimic the HMGCR knockout in adipocytes, we stably induced tamoxifen (Tamo)-activated Cre in primary WAT cells (primary Ert2Cre+ WAT). As shown in Figure 5D, Tamo treatment for 48 hr knocked out the Hmgcr gene in a concentration-dependent manner in primary Ert2Cre+ WAT cells. In particular, mRNA expression levels of Hmgcr in differentiated primary Ert2Cre+ WAT cells showed concentration-dependent reduction by Tamo treatment (Figure 5E). As we observed that Adipoq expression levels in these cells were drastically increased from 4 days after differentiation induction (Figure 5F), we assumed that the knockout program was triggered from D4 to D6. Differentiated primary Ert2Cre+ WAT cells were then treated with 10 μM Tamo and simultaneously with the MVA metabolites, as shown in Figure 5G. The stained lipid droplets and intracellular TG levels were obviously decreased in Tamo-treated adipocytes, whereas these phenotypic variations were reversed in the presence of MVA or GGPP (Figures 5G and 5H). Moreover, Hoechst staining of nuclei and the cell viability assay showed that HMGCR knockout extensively reduced the number of adipocytes and that this effect was prevented by MVA or GGPP treatment (Figures 5G and 5I). These results suggested that the disruption of the MVA synthesis pathway caused adipocyte death, which may have been due to the lack of GGPP.

Apoptosis May Be Associated with HMGCR Deficiency-Induced Adipocyte Death
We observed that smaller cells and cell debris, characteristic of apoptotic cell death, occurred in the disrupted HMGCR adipocytes upon both genetic and pharmacological manipulation (Figures 6A and S9A). Thus, we stained cells with annexin V-fluorescein isothiocyanate (annexin V) and propidium iodide (PI), which indicate early and late apoptosis, respectively. In the Lova-treated 3T3-L1 adipocytes, the numbers of cells stained with annexin V and PI were increased, and this effect was reversed by co-treatment with MVA and GGPP (Figure S9B). Consistent with this finding, Lova-treated primary WAT exhibited almost identical morphological changes (Figure 6B). In addition, Tamo-induced genetic ablation of HMGCR increased the numbers of annexin V- and PI-stained primary Ert2Cre+ WAT cells, and these phenomena were ameliorated by the addition of MVA or GGPP but not squalene or FPP (Figures 5G and S9). Moreover, Hoechst staining of nuclei and the cell viability assay showed that HMGCR knockout extensively reduced the number of adipocytes and that this effect was prevented by MVA or GGPP treatment (Figures 5G and S1). These results suggested that the disruption of the MVA synthesis pathway caused adipocyte death, which may have been due to the lack of GGPP.

GGPP Plays an Essential Role in Maintaining Adipocyte Survival by Regulating Apoptosis
To further confirm whether GGPP is the key metabolite necessary for adipocyte survival, we treated primary WAT cells with zoledronate (Zol) to inhibit GGPP synthesis (Guo et al., 2007; No et al., 2012). Zol treatment significantly decreased the lipid accumulation, number of Hoechst-stained nuclei, and cell viability (Figures 7A–7C). However, these Zol-induced effects were completely reversed by GGPP addition and only partially reversed by FPP addition, indicating that GGPP depletion caused adipocyte death (Figures 7A–7C). Moreover, Zol-induced apoptosis, as confirmed by the apoptosis staining assay and apoptosis-related gene expression, was compromised by supplementation of GGPP (Figures 7D and 7E).

Next, GGPP synthase (Ggps) was genetically down-regulated by infection of adenovirus encoding Ggps-specific short hairpin RNA (shGgps) in 3T3-L1 adipocytes overexpressing the coxsackievirus-adenovirus receptor (Figure S10A). Compared with the control group (shlacZ), all types of shGgps (shGgps#1, #2, and #3) decreased the expression of Ggps and the anti-apoptotic gene Bcl-2 and enhanced the expression of the apoptotic genes Bax and Casp3, suggesting that Ggps knockdown induced apoptosis in differentiated adipocytes (Figures S10B and S10C). Next, we performed a GGPP add-back experiment to prove that GGPP depletion is the main driver of apoptosis. As shown in Figures S10D–S10F, shGgps caused adipocyte death, whereas GGPP addition could prevent it. Furthermore, the results of apoptosis staining and relative gene expression showed that GGPP supplementation ameliorated shGgps-induced adipocyte apoptosis (Figures 7F and 7G). These findings indicate
that GGPP is the key metabolite in the MVA pathway, which is indispensable for adipocyte survival, possibly through a mechanism that modulates apoptosis.

**DISCUSSION**

The MVA biosynthesis pathway produces not only sterols but also non-sterols termed isoprenoids, such as FPP and GGPP (Casey, 1992; Goldstein and Brown, 1990). Isoprenoids have been shown to play an important role in controlling cell metabolism and viability for both cancer and normal cells, such as fibroblasts, immune-related cells, and neuronal cells (Moutinho et al., 2017; Mullen et al., 2016; Tristano and Fuller, 2006; van der Burgh et al., 2014). Here, we established HMGCR deficiency models in vivo and in vitro that indicated that the MVA pathway is essential for adipocyte survival, and that suggest that GGPP may contribute in controlling adipocyte death by regulating apoptosis.

In humans, lipodystrophy can broadly be classified into genetic and acquired types (Hegele et al., 2007). Both these lipodystrophies frequently display some metabolic phenomena, such as hepatic disorders, abnormal glucose metabolism, and dyslipidemia (Hegele et al., 2007; Ludtke et al., 2005). Consistent with phenotypic variations resulting from lipodystrophy in humans, in the current study, aKO mice exhibited lipodystrophic phenotypes along with hepatomegaly, severe diabetic symptoms, and abnormal lipid metabolism. Furthermore, these lipodystrophy-related metabolic changes have also been confirmed in different lipodystrophic mouse models, such as the A-ZIP/F1 mouse, which is the typical fatless mouse model (Moitra et al., 1998), or in mice with double knockout for insulin receptor and insulin-like growth factor 1 (Boucher et al., 2016; Softic et al., 2016). Consistent with these lipodystrophic model mice, aKO mice also presented a dramatic decrease in both WAT and BAT mass. However, Guerra et al. (2001) have shown that BAT-atrophic mice exhibit a diabetic phenotype without insulin resistance. These results suggest that at least the diabetic phenotype occurring in aKO mice mainly resulted from atrophy of WAT but not BAT.

The symptoms of lipodystrophic patients or mouse models have largely been reported; however, the phenomena differ based on the respective cause and its mechanisms. In humans, patients with acquired-type lipodystrophies have almost normal weight or are underweight, whereas genetic-type lipodystrophies have different effects on body mass index variation ranging from underweight to overweight according to the mutant gene (Hegele et al., 2007). In comparison, lipodystrophic mice generated by PPARγ disruption exhibit a decrease in body weight gain despite an increase of food intake, energy expenditure, and activity (Jones et al., 2005). The A-ZIP/F1 mouse displayed an obviously enhanced body weight and food intake with no significant variations in energy expenditure and activity (Guo et al., 2012; Moitra et al., 1998). Conversely, in the current study, aKO mice showed increased body weight, food intake, and energy expenditure but decreased locomotor activity. Thus, lipodystrophic phenotypes, such as body weight, food intake, or energy expenditure, possibly vary between cases.

PPARγ mutations represent one genetic type of lipodystrophy (Hegele et al., 2007). Our previous study reported that the MVA-derived metabolite, FPP, acts as a PPARγ ligand (Goto et al., 2011), suggesting that lipodystrophy in aKO mice possibly results from deficiency of a PPARγ ligand. However, Pio treatment failed to reverse the lipodystrophy in aKO mice, whereas it partially improved diabetic phenotypes. In addition, Pio administration significantly increased liver weight and hepatic lipid accumulation but decreased body weight in aKO mice. It has been reported that rosiglitazone treatment improved the glucose metabolism but enhanced liver weight and hepatic lipid accumulation in A-ZIP/F1 mice (Gavrilo...
et al., 2003). In contrast, in the case of patients with familial partial lipodystrophy, thiazolidinedione (TZD) treatment improved not only diabetic symptoms but also liver disorders such as steatosis and fibrosis (Brown et al., 2016). It is possible that the improved liver function with TZD treatment is due to TZD-induced adipocyte differentiation and proliferation, which helps to reverse the excess hepatic lipid storage associated with insufficient adipose tissue mass (Chao et al., 2004). Combined with these results, our findings suggest that without adequate functional adipose tissue, the liver in aKO mice may constitute the primary and major target organ of TZD action, which is related to systemic glucose and lipid metabolism.

Although local cholesterol deficiency, or that of its metabolites, might contribute to MVA pathway inhibition-induced lipodystrophy in aKO mice, many reports disagree with the cholesterol contribution in lipodystrophy. Severe genetic hypocholesterolemia has been found not to be associated with fat mass loss in humans (Tanoli et al., 2004). Moreover, in the present study, even though the plasma cholesterol level was initially higher in aKO mice and was boosted by HCD, elevated plasma cholesterol seemed to be unable to restore the adipose tissue mass. Consistent results could be found with HMGCR-disrupted adipocytes treated with cholesterol. Although the cause of lipodystrophy in aKO mice seems to weakly relate to cholesterol deficiency, the incapability of de novo steroid synthesis was not completely excluded. For instance, in adipocytes, 27-hydroxycholesterol has been identified as one of the major products synthesized de novo from cholesterol by Cyp27a1. However, in mice that were deprived of Cyp27a1, no differences in WAT and body weight gain were observed, when compared with wild-type mice (Li et al., 2014). Although further investigation is needed, these results indicate that deficiency of cholesterol, or that of its metabolites, plays a minor causative effect in lipodystrophy in aKO mice.

Notably, both lipodystrophy and obesity have been shown to exhibit several similar metabolic characteristics (Hegele et al., 2007; Ludtke et al., 2005), suggesting that adipose tissue plays an important role in metabolic homeostasis. Previous reports demonstrated that implantation of adipose tissue reversed the diabetic symptoms in A-ZIP/F1 mice (Gavrilova et al., 2000). Similarly, the present results showed that adipose tissue implantation led to dramatic recovery in all metabolic disorders in aKO mice. These phenotypic effects may have been caused by several mechanisms. First, transplanted fat grafts functionally secrete adipokines, such as adiponectin and leptin, which may contribute to the metabolic improvement. Yamauchi et al. (2001) reported that lipodystrophy-induced insulin resistance was completely reversed by combined treatment of adiponectin and leptin. In addition, it has been found that transplantation of leptin-deficient adipose tissue only minimally improved lipodystrophy-related metabolic abnormalities in A-ZIP/F1 mice (Colombo et al., 2002). Colombo et al. (2002) also showed that the contribution of fat transplantation to plasma adiponectin is very low and that leptin treatment improved metabolism without any changes in adiponectin levels. Consistent with this finding, leptin treatment and overexpression of leptin also yielded an improvement in glucose metabolism and hepatic lipid accumulation in Srebp-1c Tg and A-ZIP/F1 mice, respectively (Ebihara et al., 2001; Shimomura et al., 1999). These observations suggest that leptin is possibly a major adipokine required for the regulation of glucose and lipid metabolism when adipose tissue is lacking. Second, implanted fat grafts allow the storage of lipids such as FFA, cholesterol, and TG. Gavrilova et al. (2000) reported that at 13 weeks after transplantation in A-ZIP/F1 mice, the total weight of transplanted fat increased by approximately 1.4-fold, and that the improvement of metabolic disorders was dose dependent with transplanted fat mass. In addition, low-mass fat implantation also ameliorated the disruption of glucose and lipid metabolism without any increase of leptin (Gavrilova et al., 2000). Furthermore, TZD improved hepatic and diabetic disorders in patients with lipodystrophy concomitant with enhanced adipose tissue mass (Brown et al., 2016). In the present study, both transplanted fat pad mass and adipocyte size were enhanced, indicating that the recovered capacity for storage of lipids in adipose tissue may contribute to the improvement of metabolic disorders caused by lipodystrophy. Moreover, fat transplantation also enhanced the increase of plasma leptin in aKO mice by 14-fold, despite an overall recovery to only 35% of the level of Ctrl mice. However, whether this enhanced plasma leptin level is sufficient to repress the abnormal metabolism in aKO mice remains unclear and requires further investigation.

The MVA pathway has been implicated in multiple aspects of the cell cycle including cell differentiation, survival, and growth (Bonetti et al., 2003; Demierre et al., 2005). For example, it has been reported that the MVA pathway is essential for regulation of the proliferation and growth of vascular smooth muscle cells (Bonetti et al., 2003). Several cancers, such as colorectal cancer and melanoma, were inhibited by
administration of HMGCR inhibitors (Demierre et al., 2005). These reports suggested that MVA pathway inhibition is possibly linked to programmed cell death, i.e., apoptosis (Bonetti et al., 2003; Demierre et al., 2005; Wong et al., 2002). Similarly, in adipocytes, we found that a disrupted MVA pathway caused cell death that at least partially involved isoprenoid-regulated apoptosis. The possible involvement of co-enzyme Q10 (CoQ) deficiency or impaired GGPP-related prenylation has been reported in several cell lines, such as myocytes, hepatocytes, or tumor cells, as the underlying mechanism of HMGCR inhibition-induced apoptosis (Alizadeh et al., 2017; Auer et al., 2016; Demierre et al., 2005; Tavintharan et al., 2007). However, CoQ supplementation did not prevent Lovastatin-induced adipocyte death, and treatment of GGTI2133 and Y27632, inhibitors of geranylgeranyl transferase and Rho-associated protein kinase, respectively, did not alter the outcome of adipocyte death (data not shown), indicating that the relationship between GGPP and apoptosis is an unexpected mechanism. Although detailed information about the mechanism remains unclear, we urge persistent users of statins to take the findings of this study into consideration. Interestingly, supplementation with FPP failed to prevent HMGCR inhibition-induced cell death, although GGPP is enzymatically synthesized from FPP. This may have occurred because IPP deficiency, resulting from HMGCR impairment, could not convert FPP to GGPP (Demierre et al., 2005; Park et al., 2014), which was also confirmed in the present report. In addition, Pajvani et al. (2005) demonstrated that adipose-targeted apoptosis causes lipodystrophy. These results may underlie the strong relationship between lipodystrophy and apoptosis in aKO mice.

Obesity, a complex multifaceted disease based on an increased WAT mass, is associated with an enhanced risk for other metabolic diseases such as diabetes mellitus (Kusminski et al., 2016). Notably, adipocyte turnover is extremely low in humans, such that the adipocytes replace themselves in about 10 years, whereas most other cell types only require from several days to a few months (Shamir et al., 2016; Spalding et al., 2008). It appears that adipocyte death is rarely triggered, although the detailed mechanisms remain unclear. Previous reports have demonstrated that intracellular GGPP levels and Ggps expression levels increase during adipocyte differentiation. Moreover, Ggps gene expression levels were enhanced in WAT in both HFD-induced and ob/ob obese mouse models, as well as in diabetic db/db mice (Yeh et al., 2016; Yu et al., 2011), suggesting that GGPP may play a major role in adipocyte function. In the present study, we show that HMGCR deficiency contributed to lipodystrophy, and that this may be associated with GGPP-related regulation of apoptosis. Here, we hypothesize that GGPP is a key MVA-derived metabolite involved in maintaining adipocyte survival. Upon adipocyte expansion and maturation, increased GGPP levels may protect adipocytes from apoptosis. This hypothesis potentially suggests that adipocyte turnover may be regulated through modulation of the MVA pathway. However, further investigation is needed to clarify this hypothesis.

Overall, our results demonstrate that adipose-specific disruption of the MVA pathway causes lipodystrophy and results in several metabolic variations such as abnormal glucose and lipid metabolism, as well as hepatic disorders. Here, we propose one possible mechanism wherein GGPP deficiency in adipocytes underlies these phenotypes. Moreover, the lipodystrophy mediated by MVA pathway inhibition possibly resulted from GGPP deficiency-induced adipocyte apoptosis. Our hypothesis provides insight regarding the potential mechanisms to control adipocyte turnover through regulation of the MVA pathway, as a potential therapeutic strategy for obesity. Furthermore, these findings might provide useful information for the clinical application of statin.

Limitations of the Study
We showed that GGPP deficiency induced apoptosis in adipocytes, suggesting that the MVA pathway is critical for adipocyte survival. However, owing to technical limitations, we could not quantify GGPP in adipocytes and adipose tissue. Therefore, we do not know the exact amount of GGPP required to ensure adipocyte survival. A main concern is regarding why blood circulation could not provide sufficient MVA or GGPP to compensate the HMGCR deficiency-induced lipodystrophy. Furthermore, we do not know whether the role of inhibited HMGCR in human adipocyte is consistent with that shown in the present study, because we used a mouse and mouse-derived cell models. Although we cannot provide any information about these issues, we aim to address such important issues in future studies to better understand the physiological function of GGPP.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION

Supplemental Information includes Transparent Methods, ten figures, and two tables and can be found with this article online at https://doi.org/10.1016/j.isci.2018.10.019.

ACKNOWLEDGMENTS

The authors sincerely thank Prof. Yoshihiro Ogawa (Kyushu University, Fukuoka, Japan) who kindly provided CAR-L1 cells. The authors are grateful to Prof. Yasutomi Kamei (Kyoto Prefectural University, Kyoto, Japan) who kindly gave us the ERT2-Cre retroviral expression vector. The authors also thank S. Shinotoh and R. Yoshii for secretarial, and M. Komori for technical support. This study was supported by Grants-in-Aid for Scientific Research Grants from the Ministry of Education, Culture, Sports, Science and Technology, Japan (16H02551, 16K07734).

AUTHOR CONTRIBUTIONS

Y.-S.Y. performed the majority of the experiments and wrote the manuscript. M.K. conducted fat transplantation. H.-F.J., M.I., M.K., S.M., J.K., S.K., and Y.L. helped with animal experiments. H.-F.J., H.T., T.A., and W.N. provided expertise and feedback. H.-F.J. and T.G. revised and reviewed the article. T.K. and T.G. conceived and supervised the project.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

Alizadeh, J., Zeki, A.A., Mirzaei, N., Tewary, S., Rezaie Moghadam, A.; Glogowska, A., Nagakannan, P., Efekharpour, E., Wiechec, E., Gordon, J.W., et al. (2017). Mevalonate cascade inhibition by simvastatin induces the intrinsic apoptosis pathway via depletion of isoprenoids in tumor cells. Sci. Rep. 7, 44841.

Auer, J., Sinzinger, H., Franklin, B., and Berent, R. (2016). Muscle- and skeletal-related side-effects of statins: tip of the iceberg? Eur. J. Prev. Cardiol. 23, 88–110.

Bang, C.N., and Okin, P.M. (2014). Statin treatment, new-onset diabetes, and other adverse effects: a systematic review. Curr. Cardiol. Rep. 16, 461.

Bays, H.E., Toth, P.P., Kris-Etherton, P.M., Abate, N., Aronne, L.J., Brown, W.V., Gonzalez-Campoy, J.M., Jones, S.R., Kumar, R., La Forge, R., et al. (2013). Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J. Clin. Lipidol. 7, 306–383.

Bonetti, P.O., Lerman, L.O., Napoli, C., and Lerman, A. (2003). Statin effects beyond lipid lowering—are they clinically relevant? Eur. Heart J. 24, 225–248.

Boucher, J., Sofic, S., El Ouaamari, A., Krumpoch, M.T., Kleinridders, A., Kulkarni, R.N., O’Neill, B.T., and Kahn, C.R. (2016). Differential roles of insulin and IGF-1 receptors in adipose tissue development and function. Diabetes 65, 2201–2213.

Brault, M., Ray, J., Gomez, Y.H., Mantzoros, C.S., and Daskalopoulou, S.S. (2014). Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 63, 735–745.

Brown, R.J., Araujo-Vilar, D., Cheung, P.T., Dungan, D., Garg, A., Jack, M., Mungai, L., Oral, E.A., Patni, N., Rother, K.I., et al. (2016). The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J. Clin. Endocrinol. Metab. 101, 4500–4511.

Casey, P.J. (1992). Biochemistry of protein prenylation. J. Lipid Res. 33, 1731–1740.

Chao, P.J., Tsai, J.C., Chang, D.M., Shin, S.J., and Lee, Y.J. (2004). A case of acquired generalized lipodystrophy with cerebellar degeneration and type 2 diabetes mellitus: The review of diabetic studies. Rev. Diabet. Stud. 1, 195–197.

Colombo, C., Cutson, J.J., Yamauchi, T., Vinson, C., Kadotaw, K., Gavrilova, O., and Reitman, M.L. (2000). Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipodystrophy. Diabetes 51, 2727–2733.

Demierre, M.F., Higgins, P.D., Gruber, S.B., Hawk, E., and Lippman, S.M. (2005). Statins and cancer prevention. Nat. Rev. Cancer 5, 930–942.

Ebihara, K., Ogawa, Y., Masuzaki, H., Shintani, M., Miyanaga, F., Aizawa-Abe, M., Hayashi, T., Miyanaga, F., Aizawa-Abe, M., Hayashi, T., Hosoda, K., Inoue, G., Yoshimasa, Y., et al. (2001). Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipodystrophic diabetes. Diabetes 50, 1440–1448.

Eguchi, J., Wang, X., Yu, S., Kershaw, E.E., Chiu, P.C., Dushay, J., Estall, J.I., Klein, U., Maratos-Flier, E., and Rosen, E.D. (2011). Transcriptional control of adipose lipid handling by IRF4. Cell Metab. 13, 249–259.

Fasshauer, M., and Bluher, M. (2015). Adipokines in health and disease. Trends Pharmacol. Sci. 36, 461–470.

Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J.J., Johnson, L., Dietz, K.R., Nicol, C.J., Vinson, C., Gonzalez, F.J., and Reitman, M.L. (2003). Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278, 34268–34276.

Gavrilova, O., Marcus-Samuels, B., Graham, D., Kim, J.K., Shulman, G.I., Castle, A.L, Vinson, C., Eckhaus, M., and Reitman, M.L. (2000). Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 105, 271–278.

Goldstein, J.L., and Brown, M.S. (1990). Regulation of the mevalonate pathway. Nature 343, 425–430.

Goto, T., Naga, H., Egawa, K., Kim, Y.I., Kato, S., Taimatsu, A., Sakamoto, T., Ebisu, S., Hoshaka, T., Miyagawa, H., et al. (2011). Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARgamma agonist. Biochem. J. 438, 111–119.

Guerra, C., Navarro, P., Valverde, A.M., Arribas, M., Bruning, J., Kozak, L.P., Kahn, C.R., and Benito, M. (2001). Brown adipose tissue-specific
insulin receptor knockout shows diabetic phenotype without insulin resistance. J. Clin. Invest. 108, 1205–1213.

Guo, R.T., Cao, R., Liang, P.H., Ko, T.P., Chang, T.H., Hudock, M.P., Jeng, W.Y., Chen, C.K., Zhang, Y., Song, Y., et al. (2007). Bisphosphonates target multiple sites in both cis- and trans-prenytransferases. Proc. Natl. Acad. Sci. U S A 104, 10022–10027.

Guo, T., Bond, N.D., Jou, W., Gavriloa, O., Portas, J., and McPherron, A.C. (2012). Myostatin inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy. Diabetes 61, 2414–2423.

Hegele, R.A., Joy, T.R., Al-Attar, S.A., and Rutt, B.K. (2007). Thematic review series: adipocyte Biology. Lipidoprophies: windows on adipose biology and metabolism. J. Lipid Res. 48, 1433–1444.

Jones, J.R., Barrick, C., Kim, K.A., Lindner, J., Blondeau, B., Fujimoto, Y., Shioti, M., Kesterson, R.A., Kahn, B.B., and Magnuson, M.A. (2005). Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc. Natl. Acad. Sci. U S A 102, 6207–6212.

Kamal, S., Khan, M.A., Seth, A., Cholankeril, G., Gupta, D., Singh, U., Kamal, F., Howden, C.W., Stave, C., Nair, S., et al. (2017). Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 112, 1495–1505.

Krause, B.R., and Hartman, A.D. (1984). Adipose tissue and cholesterol metabolism. J. Lipid Res. 25, 97–110.

Kusminski, C.M., Bickel, P.E., and Scherer, P.E. (2016). Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat. Rev. Drug Discov. 15, 639–660.

Lackey, D.E., and Olefsky, J.M. (2016). Regulation of metabolism by the innate immune system. Nat. Rev. Endocrinol. 12, 15–28.

Li, J., Daly, E., Campioli, E., Wabisch, M., and Papadopoulos, V. (2014). De novo synthesis of steroids and oysterol in adipoctyes. J. Biol. Chem. 289, 747–764.

Ludtke, A., Genschel, J., Brabant, G., Bauditz, J., Taupitz, M., Koch, M., Wemke, W., Worman, H.J., and Schmidt, H.H. (2005). Hepatic steatosis in Dunngan-type familial partial lipodystrophy. Am. J. Gastroenterol. 100, 2218–2224.

Moitra, J., Mason, M.M., Olive, M., Krylov, D., Gavriloa, O., Marcus-Samuels, B., Fegenbaum, L., Lee, E., Aoyama, T., Eckhaus, M., et al. (1998). Life without white fat: a transgenic mouse. Genes Dev. 12, 3168–3181.

Moutinho, M., Nunes, M.J., and Rodrigues, E. (2017). The mevalonate pathway in neurons: it’s not just about cholesterol. Exp. Cell Res. 360, 55–60.

Mullen, P.J., Yu, R., Longo, J., Archer, M.C., and Penn, L.Z. (2016). The interplay between cell signalling and the mevalonate pathway in cancer. Nat. Rev. Cancer 16, 716–731.

Nagashima, S., Yagyu, H., Ohashi, K., Tazoe, F., Takahashi, M., Ohshiro, T., Bayasgalan, T., Okada, K., Sekiya, M., Osuga, J., et al. (2012). Liver-specific deletion of 3-hydroxy-3-methylglutaryl coenzyme A reductase causes hepatic steatosis and death. Arterioscler. Thromb. Vasc. Biol. 32, 1824–1831.

No, J.H., de Macedo Dossin, F., Zhang, Y., Liu, Y.L., Zhu, W., Feng, X., Yoo, J.A., Lee, E., Wang, K., Hui, R., et al. (2012). Lipophilic analogs of zoledrionate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity. Proc. Natl. Acad. Sci. U S A 109, 4058–4063.

Ozaki, Y., Nakagawa, Y., Miyahara, S., Iwasaki, H., Arai, I., Matsuoka, T., Kobayashi, K., Yatoh, S., Ichishi, A., Tahashi, Y., Yahagi, N., et al. (2015). Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: a model for statin-induced myopathy. Biochem. Biophys. Res. Comm. 464, 536–540.

Pajvani, U.B., Trujillo, M.E., Combs, T.P., Iyengar, P., Jelicks, L., Roth, K.A., Kittis, R.N., and Scherer, P.E. (2005). Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipolysis. Nat. Med. 11, 797–803.

Park, J., Matsulis, A.N., Berghuis, A.M., and Tsantrizos, Y.S. (2014). Human isoprenoid synthase enzymes as therapeutic targets. Front. Chem. 2, 50.

Shamir, M., Bar-On, Y., Phillips, R., and Milo, R. (2013). Egr-1 decreases adipocyte insulin sensitivity by tilting PI3K/Akt and MAPK signal transduction in vivo. Diabetes 62, 1317–1322.

Yu, X., Shen, N., Zhang, M.L., Pan, F.Y., Wang, C., Jia, W.P., Liu, C., Gao, Q., Gao, X., Xue, B., et al. (2011). Egri-1 decreases adipocyte insulin sensitivity by tilting PI3K/Akt and MAPK signal balance in mice. EMBO J. 30, 3734–3745.

Zaharan, N.L., Williams, D., and Bennett, K. (2013). Statins and risk of treated incident diabetes in a primary care population. Br. J. Clin. Pharmacol. 75, 1118–1124.
Supplemental Information

The Mevalonate Pathway Is Indispensable for Adipocyte Survival

Yu-Sheng Yeh, Huei-Fen Jheng, Mari Iwase, Minji Kim, Shinsuke Mohri, Jungin Kwon, Satoko Kawarasaki, Yongjia Li, Haruya Takahashi, Takeshi Ara, Wataru Nomura, Teruo Kawada, and Tsuyoshi Goto
Figure S1. Specific Disruption of the Hmgcr, Related to Figure 1 and 2

(A) Strategy for conditional deletion of Hmgcr

(B) DNA was amplified by PCR to check the Hmgcr alleles. The floxed and knockout alleles are 2757 and 519 bp, respectively.
Figure S2. Lipodystrophy in Female aKO Mice and its Phenotypes, Related to Figure 1 and 2

(A) Body weight change of female control (Ctrl) and aKO mice.
(B) Relative fat and lean mass levels of 15-week-old female Ctrl and aKO mice.

(C) Adipose tissue weight of female Ctrl and aKO mice at 32 weeks of age.

(D and E) Plasma adiponectin (D) and leptin (E) levels in female Ctrl and aKO mice quantified at 32 weeks of age.

(F and G) Food intake (F) and water consumption (G) of female Ctrl and aKO mice as measured from 14 to 32 weeks of age.

(H and I) Plasma glucose (H) and insulin (I) levels as analyzed in the 32-week-old female Ctrl and aKO mice.

(J) GTT in female Ctrl and aKO mice as performed at 16 weeks of age.

(K) ITT in female Ctrl and aKO mice as performed at 18 weeks of age.

(L) Gross morphology of the liver in female Ctrl and aKO mice at 32 weeks of age.

(M) Hepatic lipid accumulation levels in 32-week-old female Ctrl and aKO mice.

(N) Plasma GOT and GPT activity in 32-week-old Ctrl and aKO mice.

(O-Q) Locomotor activity (O), oxygen consumption (P), and RER (Q) as detected from 20 to 25 weeks of age in female Ctrl and aKO mice.

(R) Plasma TG, FFA, cholesterol, and β-HB levels in 32-week-old female Ctrl and aKO mice.

All mice were fed ND. Bars represent the mean ± SE. (n = 4–8). Significant differences were determined by Student’s *t* test compared with Ctrl: *p < 0.05, **p < 0.01, ***p < 0.001.
Figure S3. Effect of HFD on Lipodystrophic aKO Mice, Related to Figure 1 and 2

(A) Body weight change of control (Ctrl) and aKO mice from 8 weeks of age.

(B) Adipose tissue weights of Ctrl and aKO mice.

(C) Gross morphology of iWAT, eWAT, BAT, and the liver (from top to bottom) of Ctrl and aKO mice.

(D and E) Plasma adiponectin (D) and leptin (E) levels in Ctrl and aKO mice.

(F and G) Plasma glucose (F) and insulin (G) levels as analyzed in the Ctrl and aKO mice.

These results were obtained after administration of HFD for 20 weeks in 8-week-old Ctrl and aKO mice. Bars represent the mean ± SE. (n = 6). Significant differences were determined by Student’s t test compared with Ctrl: *p < 0.05, ***p < 0.001.
Figure S4. Pio Treatment Partially Improves Diabetic Phenotypes in aKO Mice Without Increased Adipose Tissue Mass, Related to Figure 1 and 2

(A and B) Body weight (A) and relative fat mass (B) changes of control (Ctrl) and aKO mice during Pio treatment.

(C) Adipose tissue weights of Ctrl and aKO mice after 10-week Pio treatment.

(D) Gross morphology of eWAT (top panel) and the liver (bottom panel). Hepatic TG accumulation levels and plasma GOT and GPT activity were measured.

(E and F) Plasma adiponectin (E) and leptin (F) levels of Ctrl and aKO mice after 10-week Pio treatment.

(G and H) Food intake (G) and water consumption (H) of Ctrl and aKO mice as measured from 5 to 10 weeks after Pio treatment.

(I and J) Plasma glucose (I) and insulin (J) levels of Ctrl and aKO mice after 10-week Pio treatment.
Bars represent the mean ± SE. \( n = 6-7 \). Bars with different letters represent significant differences \( (p < 0.05) \) by one-way ANOVA with a post-hoc Tukey HSD test. Veh, vehicle.
Figure S5. Successful WAT Transplantation as Confirmed in aKO Mice, Related to Figure 3 and 4

(A) Gross morphology of the back (left) and weight change (right) of transplanted WAT at 16 weeks after surgery.

(B) At 2 weeks after fat implantation, blood vessels were confirmed in fat grafts. Arrows indicate the blood vessels.

(C) Sections from adipose tissue before and at 16 weeks after transplantation as stained with H&E. Scale bars represent 200 μm.
Figure S6. Effect of Lova-Inhibited HMGCR on Differentiated 3T3-L1 Adipocytes, Related to Figure 5

(A-C) After 3T3-L1 cells were differentiated and kept until D4, they were treated with 10 μM Lova in combination with or without MVA metabolites for an additional 4 days (A). The lipids and nuclei were stained with Nile red (top panel) and Hoechst 33324 (middle panel) (A). Lipid accumulation levels (B) and cell viability (C). Scale bars represent 200 μm.

MVA metabolites included 30 μM MVA, 30 μM squalene, 10 μM FPP, and 10 μM GGPP. Bars represent the mean ± SE. (n = 6). Bars with different letters represent significant differences (p < 0.05) by one-way ANOVA with a post-hoc Tukey HSD test.
Figure S7. Combination of FPP and IPP Can Prevent Lova-induced Adipocyte death, Related to Figure 5

(A-C) After primary WAT cells were differentiated and kept until D4, they were treated with 10 μM Lova in combination with or without MVA metabolites for an additional 4 days (A). The lipids and nuclei were stained with Nile red (top panel) and Hoechst 33324 (middle panel) (A). Lipid accumulation levels (B) Scale bars represent 200 μm.

MVA metabolites included 10 or 30 μM IPP, 10 μM FPP, and 10 μM GGPP. Bars represent the mean ± SE. (n = 3-4). Bars with different letters represent significant differences (p < 0.05) by one-way ANOVA with a post-hoc Tukey HSD test.
Figure S8. Cholesterol Treatment Fails to Prevent the Adipocyte Death Caused by MVA Pathway Inhibition, Related to Figure 5

(A and B) After primary WAT cells were differentiated and kept until D4, they were treated with 10 μM Lova in combination with or without 30 μM cholesterol for an additional 4 days. The lipids and nuclei were stained with Nile red (top panel) and Hoechst 33324 (middle panel) (A). Lipid accumulation levels (B). Scale bars represent 200 μm.
Bars represent the mean ± SE. (n = 6). Bars with different letters represent significant differences (p < 0.05) by one-way ANOVA with a post-hoc Tukey HSD test.

(C) Plasma cholesterol levels of Ctrl and aKO mice during feeding HCD.

(D) Adipose tissue weights of Ctrl and aKO mice after 6-week HCD treatment.

(E) Gross morphology of iWAT (top panel) eWAT (middle panel) and BAT (bottom panel) after 6-week HCD treatment.

(F and G) Plasma adiponectin (F) and leptin (G) levels of Ctrl and aKO mice after 6-week HCD treatment. Bars represent the mean ± SE. (n = 4). Bars with different letters represent significant differences (p < 0.05) by one-way ANOVA with a post-hoc Tukey HSD test.
Figure S9. Lova Treatment Induces Apoptosis in Differentiated 3T3-L1 Adipocytes, Related to Figure 6

(A-B) After 3T3-L1 cells were differentiated and kept until D4, they were treated with 10 μM Lova in combination with or without MVA metabolites for an additional 4 days. Morphological observation of HMGCR-inhibited 3T3-L1 cells. Arrows indicate shrunken adipocytes (A). Annexin V (top panel) and PI (middle panel) staining was performed in differentiated 3T3-L1 adipocytes (B). Scale bars represent 200 μm. MVA metabolites included 30 μM MVA, 30 μM squalene, 10 μM FPP, and 10 μM GGPP.
Figure S10. Knockdown of GGPP Synthase Induces Adipocyte Death, Related to Figure 7

(A-C) After coxsackie-adenovirus receptor (CAR)-overexpressed 3T3-L1 (CAR-L1) cells were differentiated and kept until D4, they were infected with adenovirus encoding Ggps-specific short hairpin RNA (shGGPS) or with control adenovirus encoding shRNA for lacZ gene in combination with or without GGPP for an additional 4 days (A). Ggps mRNA levels (B). Apoptosis-related gene expression (C).

(D-F) Differentiated CAR-L1 cells were infected with shGGPS#2 or shlacZ adenovirus in combination with or without 10 μM GGPP for an additional 4 days. The lipids and nuclei in CAR-L1 cells were stained with Nile red (top panel) and Hoechst33342 (middle panel), respectively (D). TG accumulation levels (E) and cell viability (F) are also shown. Scale bars represent 200 μm.
### Table S1. Primers obtained for PCR amplification, Related to Figure 2, 4, 5, 6 and 7

| Gene      | Forward primer              | Reverse primer              | Gene ID |
|-----------|-----------------------------|----------------------------|---------|
| Acox1     | ACCTTCACTTGGGACATGTC       | TTCCAAGCCTCGAAGATGAG       | 11430   |
| Acta2     | GTACCACCATGTACCCAGGC       | GCTGGAAGTGAGACAGCGA         | 11475   |
| Adgre1    | TTTTCTCCGCTTCCTTTCTC       | CCCCCTCTCTCTATTCAACC       | 13733   |
| Adipoq    | TACAACCAACAGATCATTATGACGG | GAAAGCCAGTAATGTAGAGTCTGTTGA | 11450   |
| Bax       | GAGCTGCAAGAGATGATTGC       | CTGGGATCCAGAAGACAGC         | 12028   |
| Bcl2      | GTCGCTACGGTGCTGACTTC       | CTGGGGCCATATAGTTCCACAA     | 12043   |
| Casp3     | GAGCTTGGGAGGCTAGC          | CATCCTCGTACCAAGCAGG         | 12367   |
| Col1a1    | TCCAGCTTGTGGACCTCCG        | GGACCCCTAGGCGACTTGT        | 12842   |
| Cpt1a     | CTCACTGGGAGCGACTCCTTCA     | GCCTCTGTGGGTACAGC          | 12894   |
| Fasn      | AGGACTTGGGCTGACTACA        | GGAGCTATGAGATGTGGTGA        | 14104   |
| Fbp1      | GGACATTGACCTCCGATCA        | GGTCCTTTCTCTGATGATC         | 14121   |
| Fn1       | GTGGCTGCTCTTAACCTTCTC      | GTGGGGTGCAACCTTCAAT         | 14268   |
| G6pc      | GCTGGAGTCTTGTGCCAGCAT      | ATCCAAGCGAAGAAACCAACAC     | 14377   |
| Ggps      | CACTAGTGGGCTTTAGCGACC      | GAGTGCTCTGAGACAGCTAC       | 14593   |
| Hmgcr     | GAGGGCCTTTGATAGCACC        | TACCAGCTGCTTTCTCCGT        | 15357   |
| Itgax     | TGAGATTTGTCTTGTCTTGT       | GCCTGTGTGATGCCCACATT       | 16411   |
| Pck1      | AGGAGAGTGTCGCGGAGCTT       | TTTTTCTCGAGCTGAGCA         | 18534   |
| Ppara     | TCGCCTACGGCGAATGGGTTT      | ATCCATCTCCGAGTTAAGGAGG     | 19013   |
| Pparg     | GGAGATCTCCAGTATACGCAA      | ACGGCTTCTACGAGATCCAA       | 19016   |
| Rplp0     | TCCCTCTCAGCGCTTTGG         | GCACACCTCGAAAGCCCG         | 11837   |
| Srebf1    | GGAGCCATTGGGTACTGCAAT      | GCCAGAGAGAAGAGAAAGAGAAG    | 20787   |
| Tgfβ1     | GCAACATGTGGAACTCTACCAA     | AGCTCAAAGAGACGACCCTCA      | 21803   |
| Tnf       | ACATCGACATCTCTTCTCAATTC    | GTTGTTGAGGAGCGACGTAGT      | 21926   |
| Hmgcr     | TTACTGGCTTGCTCGCTTCCA      | GACACATGAAGGCGATCTCCAGCGA  | 15357   |

For detecting mRNA expression levels

For analyzing DNA allele
|                  | Ctrl     | KO       |
|------------------|----------|----------|
| BW (g)           | 33.94±0.93 | 39.45±0.73 *** |
| iWAT (mg)        | 0.41±0.07  | 0.05±0.003 **  |
| eWAT (mg)        | 0.97±0.19  | 0.01±0.001 **  |
| BAT (mg)         | 0.09±0.01  | 0.01±0.001 *** |
| Liver (mg)       | 1.36±0.07  | 5.21±0.33 *** |
| Heart (mg)       | 0.14±0.01  | 0.19±0.01 *** |
| Kidney (mg)      | 0.38±0.02  | 0.58±0.03 *** |
| Gastrocnemius Muscle (mg) | 0.32±0.01 | 0.33±0.01 |

Table S2. Organs weight of male mice deleted HMGCR in adipose tissue, Related to Figure 1 and 2
**Transparent Methods**

**Reagents**

Mevalonic acid, IPP, FPP, GGPP and zoledronate were purchased from Sigma (St. Louis, MO, USA). Lovastatin, tamoxifen, and pioglitazone were obtained from Tokyo Kasei (Tokyo, Japan). Other chemicals were purchased from Sigma, Nacalai Tesque (Kyoto, Japan), or Wako Pure Chemicals (Osaka, Japan).

**Animals**

All animal experiments and maintenance were in accordance with the guidelines of the Kyoto University Animal Care Committee (approval code 28-49). Five-week-old C57BL/6 male mice were purchased from Japan SLC (Hamamatsu, Japan). All mice were housed at 23 ± 1 °C and maintained on a 12-h light/dark cycle. In all of the experiments, mice were fed a commercial chow diet (CRF-1, Charles River Japan, Kanagawa, Japan) until 8 weeks of age, and then the mice were randomly divided into groups for experiments.

**Cell lines**

3T3-L1 murine preadipocytes were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum and 100 U/ml penicillin as the growth medium at 37°C in 5% CO₂.

Primary adipose cells were prepared as in a previous study (Aune et al., 2013). Primary adipose cells were isolated from WAT of male HMGCR f/f mice and infected with ERT2-Cre expression retrovirus, which was kindly provided by Prof. Yasutomi Kamei (Kyoto Prefectural University, Kyoto, Japan). After 24 h of infection, cells were selected by 2.5 μg/ml puromycin for 1 week and used for cell culture experiments.

**Mouse Phenotype Assessment**

For examining the influence of adipose-specific HMGCR on metabolic state, the mice were fed a chow diet and sacrificed at 32 weeks of age. In the high fat diet (HFD) treatment experiment, mice were fed HFD containing 60% kcal fat (HFD, Research Diet, New Brunswick, NJ, USA) for 20 weeks. Pio treatment was administered for 10 weeks.
the high cholesterol diet treatment experiment, 18-week-old mice were fed the control diet (AIN-93M, Oriental Yeast Co., Tokyo, Japan) or AIN-93M, containing 1% (w/w) of cholesterol, for 6 weeks. To perform the GTT assay, mice were fasted for 6 h and a blood sample was taken from the mouse tail vein (0 min point). Subsequently, mice were orally treated with glucose solution (2 g of glucose/10 ml of sterile phosphate-buffered saline, 10 μl/g body weight) and blood samples were collected at different time points (15, 30, 60, and 120 min). For analysis of ITT, blood samples were collected from the mouse tail vein (0 min point) and the mice were then intraperitoneally injected with insulin solution (0.1 U of insulin/ml of sterile phosphate-buffered saline, 10 μl/g body weight) after fasting for 6 h. The blood samples were taken at 15, 30, 60, and 120 min. The oxygen consumption was measured using an indirect calorimetric system (Oxymax Equal Flow 8 Chamber/Small Subject System; Columbus Instruments, Columbus, OH, USA) equipped with an eight-chamber airtight metabolic cage. The RER was calculated by dividing the CO$_2$ production by the O$_2$ consumption. The locomotor activity was measured using an Actimo-S system (Bio Research Centre, Nagoya, Japan). For both oxygen consumption and locomotor activity measurement, mice were acclimatized to the individual experiment-specific cages for 2 hours prior to the experiment and measurement was performed from 15:00 (ZT8) to the next day at 11:00 (ZT4) in a 12-h light/dark cycle condition. Body composition was scanned using an EchoMRI 3-in-1 system (Hitachi, Tokyo, Japan), in accordance with the manufacturer’s instructions.

**Strategy and Generation of aKO mice**

The floxed HMGCR mice (HMGCR $f^f$) were generated by Unitech Co. (Chiba, Japan). Adipoq-Cre BAC transgenic mice (RRID: IMSR_JAX:010803) were purchased from Jackson Laboratory (Bar Harbor, ME, USA). To generate floxed HMGCR mice, loxP sites were introduced on either side of exons 12 and 14 of Hmgcr. Adipoq-Cre BAC transgenic mice, in which Cre recombinase is specifically expressed in adipose tissue, were used to cross floxed HMGCR mice (HMGCR $f^f$) (Figure S1A) to generate HMGCR $f^+/Cre^+$ progeny. These mice were then backcrossed to HMGCR $f^f$ mice. The backcrossed HMGCR $f^+/Cre^+$ mice were subsequently interbred to yield four derivative strains: (i) HMGCR $f^f$ (Ctrl), (ii) HMGCR $f^f$ Cre$^+$ (aKO), (iii) HMGCR $f^+$ Cre$^+$ (heterogeneous aKO), and (iv) HMGCR $f^+$. aKO mice were predicted to have adipose-specific loss of Hmgcr exons 12–14, which was expected to abolish translation of the entire carboxyhydroxylase site (Asn 281) containing the catalytic activity (Liscum et al., 1985).
Adipose Tissue Implantation

The adipose tissue implantation was performed as previous study (Gavrilova et al., 2000). To prevent rejection, donors and recipients were sex-matched. Five-week-old C57BL/6J mice were used as fat donors. Donor adipose tissues from euthanized C57BL/6J mice were placed into sterile phosphate-buffered saline and cut into 100- to 150-mg pieces. The fat grafts were implanted subcutaneously in the shaved skin of the backs of anesthetized 8-week-old aKO mice via small incisions. Into two incisions, 3 to 4 fat grafts were placed, totaling 1000 mg of fat per mouse. After surgery, mice were housed individually for 2 weeks.

Cell culture

Two days after reaching confluence (D0), 3T3-L1 cells were incubated in a differentiation medium containing 0.25 μM dexamethazone, 10 μg/ml insulin, and 0.5 mM 3-isobutyl-1-methylxanthine in the growth medium. After 48 h (D2), the cell culture medium was changed to post differentiation medium containing 5 μg/ml insulin in the growth medium, and a fresh post-differentiation medium was also supplied at Day 4 (D4). At 4 days after differentiation, 3T3-L1 cells were used for subsequent experiments. To increase the efficiency of adenovirus-regulated transduction of short hairpin RNA (shRNA), 3T3-L1 adipocytes stably expressing coxsackie-adenovirus receptor (CAR)-L1 were obtained (Ito et al., 2007). Four days after differentiation, CAR-L1 cells were re-seeded into a new plate and infected with adenovirus encoding Ggps-specific shRNA or with control adenovirus encoding lacZ, for additional 4 days. The target sequences were as follows: Ggps#1, 5ʹ-GGAACCGTACGCTTTGAAATTTA-3ʹ; Ggps#2, 5ʹ-GTCCAACTGAAGAAGATAAA-3ʹ; Ggps#3, 5ʹ-CAGCTGTCTCTGATTACAAAGA-3ʹ; lacZ control, 5ʹ-GCTACACAAATCAGCGATTT-3ʹ.

ERT2-Cre-infected HMGCR ff primary WAT cells were differentiated by a method consistent with that used for 3T3-L1 cells. For lipid staining, the adipocytes were double-stained with 10 μg/ml Nile red and 20 μM Hoechst 33324. For apoptosis staining, the Annexin V-FITC Apoptosis Detection Kit (Nacalai Tesque) was used in accordance with the manufacturer’s instructions.

Histological Analysis

The organ samples of BAT, iWAT, eWAT, and the liver were fixed in 4% paraformaldehyde. The fixed samples were
embedded in paraffin for staining with eosin Y (Wako Pure Chemicals) or embedded in O.C.T. compound (Sakura Finetek Japan, Tokyo, Japan) for staining with Oil Red O. Both eosin Y- and Oil Red O-stained cells were counterstained with modified Mayer’s hematoxylin (Merck, Darmstadt, Germany).

**Hepatic Lipid Analysis**

To quantify hepatic TG content, the lipids were extracted by 1.2 ml of hexane/2-propanol (3:2 v/v) for each 50 mg of liver samples. The liver samples were homogenized and centrifuged at 4 °C for 10 min at 10,000 × g. After drying by evaporation, the lipid extracts were resuspended in 2-propanol and determined enzymatically using the TG E-test (Wako Pure Chemicals).

**Hepatic Glycogen Analysis**

Eppendorf tubes containing 600 μl of 30% (W/V) KOH were used to extract 100 mg of each liver sample, followed by incubation at 100 °C until the sample dissolved. Then, 100 μl of saturated Na₂SO₄ and 750 μl of 95% EtOH were added and vortexed, and then incubated at 100°C until small bubbles were confirmed. The samples were centrifuged at 4°C for 10 min at 300 × g, and the supernatant was decanted to dry the samples. Then, 400 μl of distilled water and 500 μl of 95% EtOH were added to all samples and mixed. After incubation at 100°C until small bubbles formed, the samples were centrifuged at 4°C and 300 × g for 10 min. The samples were then decanted and dried, and 1.2 ml of 0.6 N HCl was added with incubation at 100 °C for 2 to 2.5 hours. From each sample, 300 μl was removed to a new Eppendorf tube containing 415 μl of 0.5 N NaOH and 285 μl of distilled water and mixed. The concentration of the samples was measured by glucose C-test.

**Analysis of Plasma Chemical Parameters**

The levels of glucose, TG, cholesterol, β-HB, FFA, GOT/GPT, leptin, insulin, and adiponectin were determined using commercially available kits: glucose C-test, triacylglycerol E-test, cholesterol E-test, autokit 3-HB, NEFA C-test, transaminase C-test (Wako Pure Chemicals), mouse/rat leptin ELISA kit, ultrasensitive mouse insulin assay kit (Morinaga Institute of Biologic Science, Yokohama, Japan), and mouse adiponectin/Acrp30 Quantikine ELISA kit.
Gene Expression Quantification

RNA was isolated with Sepasol-RNA I Super reagent (Nacalai Tesque) and then reverse-transcribed using M-MLV reverse transcriptase (Promega Corporation, Fitchburg, WI, USA). For quantifying the mRNA expression level, real-time PCR was performed using a LightCycler system (Roche Diagnostics, Mannheim, Germany) using SYBR Green fluorescence signals (AptaTaq DNA Polymerase). The protocol for amplification was as follows: denaturation, 95°C for 1 min; annealing, 60°C for 5 sec; extension, 72°C for 30 sec. All measured gene expression was normalized to the levels of ribosomal protein lateral stalk subunit P0 (Rplp0). Primer sequences are provided in Table S1.

DNA Extraction and Detection

The genomic DNA of tissue and cell samples was extracted using 100 μl of Proteinase K solution (50 mM Tris-HCl buffer pH 8.0, 25 mM EDTA, 0.5% SDS, 100 mM NaCl and Proteinase K 1 mg/ml) for incubation at 50°C overnight. After the samples were dissolved, 100 μl of sterile water and 200 μl of phenol:chloroform:isoamyl alcohol (25:24:1) were added and gently mixed. The samples were then centrifuged at 4°C for 5 min at 14,000 ×g, and 150 μl of supernatant was removed into a new Eppendorf tube and then 200 μl of chloroform was added to every sample. After centrifugation at 4°C for 5 min at 14,000 ×g, 120 μl of supernatant was collected and removed into an Eppendorf tube containing 16 μl of 3M Na-acetate and 400 μl of 99.5% ethanol. The DNA pellet was precipitated through centrifugation at 4°C for 20 min and 19,000 ×g. After the supernatant was discarded, the DNA pellet was dissolved immediately in 30 μl of TE buffer (pH 8.0). The genomic DNA was amplified using EmeraldAmp PCR Master Mix and confirmed by agarose gel electrophoresis (Watanabe et al., 2015). Primer sequences are listed in Table S1.

QUANTIFICATION AND STATISTICAL ANALYSIS

All of the results are given as the mean ± SEM. Bars in graphs represent standard errors, and significance was assessed by Student’s two-tailed t tests or one-way analysis of variance with a post-hoc Tukey HSD test. Differences
with \( p < 0.05 \) were considered statistically significant.

**Supplemental References**

Aune, U.L., Ruiz, L., and Kajimura, S. (2013). Isolation and differentiation of stromal vascular cells to beige/brite cells. Journal of visualized experiments : JoVE.

Gavrilova, O., Marcus-Samuels, B., Graham, D., Kim, J.K., Shulman, G.I., Castle, A.L., Vinson, C., Eckhaus, M., and Reitman, M.L. (2000). Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. The Journal of clinical investigation 105, 271-278.

Ito, A., Suganami, T., Miyamoto, Y., Yoshimasa, Y., Takeya, M., Kamei, Y., and Ogawa, Y. (2007). Role of MAPK phosphatase-1 in the induction of monocyte chemoattractant protein-1 during the course of adipocyte hypertrophy. The Journal of biological chemistry 282, 25445-25452.

Liscum, L., Finer-Moore, J., Stroud, R.M., Luskey, K.L., Brown, M.S., and Goldstein, J.L. (1985). Domain structure of 3-hydroxy-3-methylglutaryl coenzyme A reductase, a glycoprotein of the endoplasmic reticulum. The Journal of biological chemistry 260, 522-530.

Watanabe, M., Suzuki, Y., Uchida, K., Miyazaki, N., Murata, K., Matsumoto, S., Kakizaki, H., and Tominaga, M. (2015). Trpm7 Protein Contributes to Intercellular Junction Formation in Mouse Urothelium. The Journal of biological chemistry 290, 29882-29892.

Yeh, Y.S., Goto, T., Takahashi, N., Egawa, K., Takahashi, H., Jheng, H.F., Kim, Y.I., and Kawada, T. (2016). Geranylgeranyl pyrophosphate performs as an endogenous regulator of adipocyte function via suppressing the LXR pathway. Biochemical and biophysical research communications 478, 1317-1322.